FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial. PMID 42247155 · Graefes Arch Clin Exp Ophthalmol · 2026-Jun-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. PMID 42246654 · N Engl J Med · 2026-Jun-05 The record describes a Phase III randomized trial of obinutuzumab in primary membranous nephropathy, which is not an oncology condition. The primary efficacy endpoint is complete remission at week 104 (a categorical endpoint), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. PMID 42246414 · JAMA · 2026-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial. PMID 42248437 · Clin Gastroenterol Hepatol · 2026-Jun-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Community health worker implementation of transdiagnostic evidence-based treatment in Spanish: protocol for refinement, implementation, and a feasibility pilot RCT. PMID 42243988 · Implement Sci Commun · 2026-Jun-04 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial. PMID 42241642 · J Clin Oncol · 2026-Jun-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial. PMID 42240984 · JAMA Oncol · 2026-Jun-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention. PMID 42240800 · Intern Emerg Med · 2026-Jun-04 The record describes a systematic review of randomized phase 3/4 trials of direct oral anticoagulants (DOACs) for secondary prevention of venous thromboembolism (VTE) in non-cancer patients. The primary endpoint is symptomatic recurrent VTE, which is not an oncology time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The study population is non-cancer, and the disease is not a human malignant neoplasm. Therefore, it is excluded based on non-oncology. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early vs. delayed primary local therapy and survival in de novo metastatic prostate cancer: target trial emulation. PMID 42240667 · World J Urol · 2026-Jun-04 The record describes an observational target trial emulation of a non-drug intervention (primary-directed local therapy) for metastatic prostate cancer. It is not a randomized trial, and it does not involve a drug-containing intervention as defined by the criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial. PMID 42240564 · Clin Infect Dis · 2026-Jun-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immune checkpoint therapy in pediatric and adolescent lymphomas. PMID 42237783 · Haematologica · 2026-Jun-04 The record describes a Phase III randomized trial but does not report any time-to-event efficacy results (e.g., OS, PFS, Kaplan-Meier curves, HR). It is a protocol/conference abstract noting expected results in 2027, not an original result report of efficacy. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis. PMID 42350220 · Clin Genitourin Cancer · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials. PMID 42242425 · J Allergy Clin Immunol Pract · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| JAAD Game Changers: A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study. PMID 42242363 · J Am Acad Dermatol · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial. PMID 42237200 · Orphanet J Rare Dis · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials. PMID 42236129 · Br J Ophthalmol · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis. PMID 42234870 · JNCI Cancer Spectr · 2026-Jun-03 The record is a systematic review and meta-analysis of Phase 3 RCTs, not an original primary report of a single trial. It reports safety incidence (peripheral edema) and does not include a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety of low lipoprotein(a) levels: the FOURIER trial. PMID 42234492 · Eur Heart J · 2026-Jun-03 This is a secondary safety analysis from a cardiovascular outcomes trial (FOURIER), not a primary report of oncology efficacy. The study is not oncology-focused, and while it includes malignancy as a safety outcome, malignancy is not the primary or key secondary efficacy endpoint. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort focused on drug intervention efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Old and New Lines of Therapy Targeting Lipoprotein(a). PMID 42234287 · Curr Atheroscler Rep · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). PMID 42234197 · J Neurol · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults. PMID 42217235 · Expert Rev Neurother · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam. PMID 41997039 · Eur J Cancer · 2026-Jun-03 The record is a randomized trial with a time-to-event oncology endpoint (prostate cancer mortality) and reports original results. However, it fails the drug-intervention criterion because the intervention is PSA screening, not a drug. Therefore, it is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open pancreaticoduodenectomy in patients with periampullary carcinoma: A randomised clinical trial. PMID 42262773 · J Minim Access Surg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Obexelimab for the Treatment of IgG4-Related Disease. PMID 42233621 · N Engl J Med · 2026-Jun-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy. PMID 42230988 · Int J Obes (Lond) · 2026-Jun-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial. PMID 42230477 · Neurocrit Care · 2026-Jun-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of argipressin on intraoperative fluid administration in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC): study protocol of a randomised clinical trial (HiPress Trial). PMID 42229964 · BMJ Open · 2026-Jun-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial. PMID 42228944 · Anesth Analg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Sentinel Node Biopsy in the Neck Management of cN0 Sinonasal Squamous Cell Carcinoma: A Multicenter Pilot Trial on Safety and Feasibility. PMID 42228262 · Ann Surg Oncol · 2026-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding. PMID 42228058 · J Biopharm Stat · 2026-Jun-02 The record describes a Phase III randomized trial in advanced breast cancer with a time-to-event endpoint, but the publication is a methodological paper applying a new statistical method to trial data, not the original trial report. It does not explicitly state a drug intervention, and it is not a formal result report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. PMID 42099212 · JAMA · 2026-Jun-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial. PMID 42096239 · JAMA · 2026-Jun-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial. PMID 42345146 · Asian Pac J Cancer Prev · 2026-Jun-01 The study meets most criteria (oncology, human, randomized, Phase III, time-to-event endpoint, original results) but does not involve a drug-containing intervention as required. The intervention compares radiation therapy margins. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials. PMID 42268612 · JAMA Netw Open · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial. PMID 42234428 · JAMA Netw Open · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study. PMID 42226295 · World J Surg Oncol · 2026-Jun-01 The record describes a retrospective, multicenter study developing a prognostic biomarker (FSL score) and a nomogram. While the underlying data came from a randomized controlled trial, this publication is not a formal result report of that trial's intervention. It is a secondary, biomarker-focused analysis, and the drug intervention is not the subject of this efficacy evaluation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 42225990 · Nat Med · 2026-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. PMID 42224388 · Horm Res Paediatr · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. PMID 42223796 · Adv Ther · 2026-Jun-01 The record describes a real-world retrospective cross-sectional survey of treatment patterns, not a randomized clinical trial. It is not a primary result report of a Phase III/IIIb or Phase II/III randomized trial with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. PMID 42223386 · Ophthalmology · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. PMID 42223130 · J Clin Oncol · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| PERKS-International: A Randomized Controlled Trial Testing the Efficacy of an mHealth Application to Reduce Risk Factors for the Primary Prevention of Stroke. PMID 42220242 · Stroke · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. PMID 42159085 · Cancer · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). PMID 42096282 · Kidney360 · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. PMID 42054033 · JAMA Cardiol · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial. PMID 42043827 · JAMA Intern Med · 2026-Jun-01 The trial is eligible for oncology and human subjects but is excluded because it is a cancer screening trial (not a treatment trial), the intervention is a screening modality (not a drug), and the primary efficacy endpoint is a proportion (screening participation), not a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial. PMID 42024409 · JAMA Ophthalmol · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cerebral Oximetry in Extremely Preterm Infants: 2-Year Follow-Up of the SafeBoosC-III Randomized Clinical Trial. PMID 42008246 · JAMA Pediatr · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial. PMID 41973444 · JAMA Intern Med · 2026-Jun-01 The study is an oncology-related randomized trial involving patients with hepatocellular cancer (part of the ESLD population), but it does not meet the required criteria for inclusion. The intervention is non-drug (palliative care delivery model), and the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint. Mortality is reported but only as a secondary outcome with no time-to-event analysis specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. PMID 41934124 · Blood Coagul Fibrinolysis · 2026-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |